A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Droxidopa (Northera)

Droxidopa capsules indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic ....

First FDA approval2014-09-01
Generic availableYes · 11 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$103.5M in CY2024 Part D spend65K claims · 14K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.643/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1.63
Across all dosage forms in distribution.
Highest NADAC
$2.75
Range is tight.
Plans with PA
906 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Droxidopa used for?

Droxidopa capsules indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic ....

Is there a generic for Droxidopa?

Yes. 33 ANDAs filed at FDA, 11 generic manufacturers currently shipping.

How much does my plan pay for Droxidopa?

Across 329 Part D plans, Droxidopa averages $1.63/unit (NADAC). Lowest available: $0.643/unit. Highest in distribution: $2.75/unit.

Is Droxidopa on the FDA shortage list?

No. Droxidopa is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.